Article Archive for 20 June 2009
Helix BioPharma To Present L-DOS47 Analytical Method Development Findings At 2009 AAPS National Biotechnology Conference
Helix BioPharma Corp. (TSX, FSE: HBP) announced that Dr. Heman Chao, chief scientific officer at Helix BioPharma Corp., will be presenting a scientific poster describing L-DOS47 analytical method development findings at the 2009 American Association …
Cephalon Provides Clinical Update On Lestaurtinib In Relapsed Acute Myelogenous Leukemia
Cephalon, Inc. (Nasdaq: CEPH) announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show the benefit …
Lytix Biopharma And KAEL-GemVax Announce Joint Clinical Trial To Combine LTX-315 And GV1001 Cancer Immunotherapy
The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax announced the signing of a collaborative agreement to test lead compounds LTX-315 and GV1001 as a combination therapy for the treatment of cancer. …
